IGM Biosciences LLC

IGMS · NASDAQ

Price unavailable right now.

No price history for this range.

IGMS analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jun 27, 2025

Bull case

IGM Biosciences Inc. is positioned favorably due to its novel IgM antibody technology platform, which has shown promise in developing therapeutics for several serious medical conditions, including cancer and autoimmune diseases. The ongoing collaboration with Sanofi (SNY) to develop IgM agonists presents significant revenue potential, with nearly $3 billion in possible milestone earnings pending the successful development of viable candidates. Additionally, the differentiated safety profiles of IgM-based therapeutics may enhance their competitive edge in the expanding autoimmune treatment market, further supporting a positive outlook for the company's stock.

Bear case

IGM Biosciences Inc. faces a negative outlook primarily due to the discontinuation of its key IgM-based bispecific antibody programs, which undermines potential revenue streams and raises concerns about the company's long-term viability. Additionally, the firm's inability to secure external funding, coupled with disappointing efficacy results from current clinical candidates such as Aplitabart and Imvotamab, further exacerbates financial instability. As operational costs continue to rise amid non-revenue-generating status, the likelihood of significant fluctuations in stock price remains high, indicating a precarious position for shareholders.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.